India Pharma - Reduced Covid-19 Cases Affect IPM Growth In September: Motilal Oswal
BQ Blue’s special research section collates quality and in-depth equity and economy research reports from across India’s top brokerages, asset managers and research agencies. These reports offer BloombergQuint’s subscribers an opportunity to expand their understanding of companies, sectors and the economy.
Motilal Oswal Report
Indian pharma market growth stood at 12.4% YoY in September 2021 versus 17.7 % YoY in August 2021.
Respiratory/analgesics/gynecological exhibited a growth of 45.8%/28.1%/17.3% YoY.
Respiratory sales grew on a sequential basis, with 45.8% YoY growth in September (38.2% YoY growth in August).
At the therapy level, YoY growth was dragged by cardiac (up 2.7% YoY), diabetes (up 6.8% YoY), and vitamins-minerals-nutrients (up 2.4% YoY).
Click on the attachment to read the full report:
This report is authored by an external party. BloombergQuint does not vouch for the accuracy of its contents nor is responsible for them in any way. The contents of this section do not constitute investment advice. For that you must always consult an expert based on your individual needs. The views expressed in the report are that of the author entity and do not represent the views of BloombergQuint.
Users have no license to copy, modify, or distribute the content without permission of the Original Owner.